EUCTR2005-000021-32-DE进行中（未招募）不适用
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer - S080
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 256
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Females, having a histologically confirmed diagnosis of primary early breast cancer, with a tumor size = 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0.
- •- Have no inflammatory and no exulcerating breast cancer.
- •- Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status scale.
- •- Have not received any previous anti-tumor therapy for breast cancer.
- •- Have at least one unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST) criteria (at least 20 mm when measured by conventional techniques, i.e., mammography or magnetic resonance imaging (MRI)).
- •- Are at least 18 years but no more than 70 years of age.
- •- Have an estimated life expectancy of at least 6 months.
- •- Must have adequate organ function that includes the following indices:
- •Bone marrow reserve: absolute neutrophil (segmented and bands) count (ANC) =1.5 X 10E9/L, platelet count =100 X 10E9/L, and hemoglobin =9 g/dL.
- •Hepatic: bilirubin <=1.5 times the upper limit of normal (x ULN), alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) <=3 X ULN.
- •Renal: serum creatinine <=1.25 mg/dL and calculated creatinine clearance (CrCl) =45 mL/min by using the standard Cockcroft and Gault formula.
- •- Must have normal cardiac function, as measured by means of physiological examination and electrocardiogram. Left ventricular ejection fraction must be >55%, as measured by nuclear medicine or echocardiogram.
- •- Must be compliant and have geographic proximity that allows adequate follow-up.
- •- Must have signed informed consent.
- •- Females of child-bearing potential: Must use a medically approved contraceptive regimen during and for 6 months after treatment; must have a negative serum pregnancy test and must not be lactating.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
- •- Have received prior anthracyclines as part of prior anticancer therapy
- •- Receive any other concurrent antitumor therapy.
- •- Have a second primary malignancy, except carcinoma in situ of the cervix or adequately treated non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence.
- •- Have a serious concomitant systemic disorder (eg, active infection including HIV, or cardiac disease) that, in the opinion of the investigator, would compromise the patient’s ability to complete the study, or have any other disease that could be worsened by chemotherapy or other potential support therapies.
- •- Have a history of auricular-ventricular arrhythmias and/or congestive heart failure, even where it is under medical control, or active second or third degree cardiac block, have a history of myocardial infarction within the last 6 months prior to recruitment, or have non-controlled or malignant high arterial blood pressure.
- •- Have a history of hypersensitivity to the drugs under study or earlier allergic reactions to the compounds containing cremophor, such as teniposide, cyclosporin or Vitamin K.
- •- Have pre-existing sensorial or motor neuropathy > grade 1.
- •- Are unable or unwilling to take dexamethasone, folic acid, Vitamin B12, or dexamethasone supplementation.
- •- Are unable to interrupt aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) for a 5-day period starting 2 days before administration of pemetrexed (8-day period for long-acting agents such as piroxicam).
研究者
相似试验
进行中（未招募）
不适用
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancereoadjuvant chemotherapy in operable breast cancerMedDRA version: 14.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-000021-32-ITELI LILLY256
进行中（未招募）
1 期
A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer - N/AFemales with histologically confirmed diagnosis of primary early breast cancer, with a tumor size = 2 cm, of Stages T2-T4/N0-2/, as confirmed by incisional or core biopsy M0 will be treated with chemotherapy prior to surgery..EUCTR2005-000021-32-ESilly S.A.256
已完成
不适用
A randomised phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinomaCancerISRCTN53872240Erasmus Medical Centre (Netherlands)30
招募中
不适用
A randomized phase II study of doxorubicin combined with thalidomide versus doxorubicin alone for patients with unresectable hepatocellular carcinoma.hepatocellular cancerNL-OMON21497ot applicable30
进行中（未招募）
1 期
A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of refractory or recurrent small cell lung carcinoma after platinum derivatives and etoposide, for which no standard treatment is available in this indication.EUCTR2008-004278-41-BEInstitut Jules Bordet43